Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044070 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00044070: Completed Phase 2 study, sponsored by Astellas Pharma.
NCT00044070 is a Phase 2 study that has completed, run by Astellas Pharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044070, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke. The study will determine if a 24-hour infusion of YM872, given within 6 hours of stroke onset, reduces the ischemic lesion volume as measured by MRI at 28 days after the infusion is given. The clinical effects of YM872 will also be determined by neurological function and disability scores at follow up visits through Day 90 of the study.
Interventions
- DRUG YM872 (zonampanel)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00044070 record still lists
NCT00044070 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which YM872 (zonampanel) is the first listed.
NCT00044070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044070 about?
NCT00044070 is a clinical study titled "A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients". This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke. The study will determine if a 24-hour infusion of YM872, given within 6 hours of stroke onset, reduces the ischemic lesion volume as measured by MRI at 28 days after the...
What is the current status of trial NCT00044070?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-12. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00044070?
The interventions under investigation include: YM872 (zonampanel) (DRUG).
Who is sponsoring clinical trial NCT00044070?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia